Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight weeks of hCG androgen priming before IVF/ICSI in women with low ovarian reserve
2020-002453-26Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human chorionic gonadotrophin in female infertility and Diminished Ovarian Reserve (DOR), sponsored by Rigshospitalet. Primary endpoint: Follicular output rate. Started Jun 2020; status: completed.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
female infertilityDiminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on 2020-002453-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002453-26.